Quality‐of‐life outcomes in patients with advanced melanoma: A review of the literature

Summary For patients with metastatic melanoma, the emergence of immune checkpoint inhibitors and targeted BRAF and MEK inhibitors has markedly enhanced clinical outcomes compared with chemotherapy. However, these novel agents are also associated with unique sets of adverse events, and increased over...

Full description

Saved in:
Bibliographic Details
Published in:Pigment cell and melanoma research 2017-11, Vol.30 (6), p.511-520
Main Authors: Malkhasyan, Karen A., Zakharia, Yousef, Milhem, Mohammed
Format: Article
Language:English
Subjects:
Chemotherapy
Clinical trials
Clinical Trials as Topic
Decision making
Health care
Humans
Immune checkpoint inhibitors
Immunotherapy
Inhibitors
Literature reviews
Medical research
MEK inhibitors
Melanoma
Melanoma - pathology
Melanoma - therapy
Metastases
Metastasis
Neoplasm Staging
Patients
Perception
Quality of Life
targeted therapy
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary For patients with metastatic melanoma, the emergence of immune checkpoint inhibitors and targeted BRAF and MEK inhibitors has markedly enhanced clinical outcomes compared with chemotherapy. However, these novel agents are also associated with unique sets of adverse events, and increased overall survival can lead to prolonged exposure to some novel agents. Therefore, clinical evaluation of these therapies has now included the analysis of health‐related quality of life (HRQoL) in addition to more traditional efficacy and safety outcomes as a measure of patient perception of benefit. The current review focuses on HRQoL outcomes in clinical trials of immune checkpoint inhibitors and targeted therapies in patients with advanced and metastatic melanoma to inform healthcare providers about patient perception of HRQoL as a new perspective in treatment decision making.
ISSN:1755-1471
1755-148X
DOI:10.1111/pcmr.12647